

MONITORING VISIT FOLLOW-UP LETTER

To: Dr. David O'Connor, Sydney Cancer Center
From: CRA / Clinical Operations -- NexaVance Therapeutics
Re: Protocol NVX-1218.22 -- Follow-up to IMV-2
Date: 2024-12-06

Dear Dr. David O'Connor,

Thank you for your time and co-operation during the recent monitoring visit to Sydney Cancer Center. This letter summarises the outstanding action items identified during the visit that require your attention and follow-up prior to the next monitoring visit.

Please review the action items listed and ensure resolution by the due dates indicated. Please confirm completion of each action item in writing to the CRA.

Outstanding Action Items

Please refer to the attached Monitoring Visit Report for full details of each finding.

If you have any questions regarding the action items listed, please do not hesitate to contact your assigned CRA. We appreciate your ongoing commitment to this important study.

CRA Signature